Vitamin prices have fallen, but it has not impacted performance; Zhejiang Nhu and Brother Enterprises Holding's Q1 performance remained basically stable compared to the previous quarter | Interpretations
① Zhejiang Nhu and Brother Enterprises Holding achieved a strong start in their performance in the first quarter of this year; ② Due to the influence of the order cycle, the price drop in Vitamins has not yet significantly impacted manufacturers' performance in the first quarter of this year; ③ In April, Vitamin prices continued to decline, putting short-term pressure on manufacturers' performance.
How is United Imaging Medical using AI to change diagnosis and treatment?
United Imaging, which integrates multimodal large models with Asia Vets applications, is reshaping the way medical work is performed.
The Peking State-owned Assets Supervision and Administration Commission proposed to effectively maintain the Market Cap of listed companies. Institutions are Bullish on the allocation value of central state-owned enterprises.
① Recently, the State-owned Assets Supervision and Administration Commission of Peking held a symposium for municipal state-owned enterprises and publicly listed companies, firmly maintaining the stability of the Capital Markets and fully promoting the high-quality development of listed companies. ② China International Capital Corporation stated that the related systems for Market Cap management of central state-owned enterprises are expected to continue improving, and the motivation for central state-owned enterprises to engage in Market Cap management in practice is also expected to continue strengthening. It is advised to pay attention to the allocated value of the Market Cap management theme of central state-owned enterprises.
The price increase of Vitamins helped Xiamen Kingdomway Group achieve a 24% increase in net profit last year, while the gross profit margin of the core product coenzyme Q10 continued to be under pressure.|Interpretations
① Xiamen Kingdomway Group had a poor start but ended strong last year, meeting Brokerage expectations; ② The price increase of VA was the main reason for the performance growth, but prices have dropped to low levels this year; ③ Core product coenzyme Q10 has seen strong production and sales but the gross profit continues to decline.
Rare! A-share announcement of a repurchase wave: the Zhongshan system, Moutai, Midea, and GTJA have all joined in.
A-shares listed companies act with confidence, injecting stable signals into the market.
Pacira BioSciences Settles Litigations With Fresenius Kabi USA, Jiangsu Hengrui Pharmaceuticals Co., Ltd., And EVenus Pharmaceuticals Laboratories Related To Patents For EXPAREL